Literature DB >> 29359367

Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.

Meriem Benfodda1,2, Steven Gazal3,4, Vincent Descamps1,3,5, Nicole Basset-Seguin1,3,6, Lydia Deschamps3,7, Luc Thomas8, Celeste Lebbe1,3,6, Philippe Saiag9, Roberto Zanetti10, Lidia Sacchetto10,11,12,13, Giovanna Chiorino10, Maria Scatolini14, Bernard Grandchamp2,3, Armand Bensussan1,3, Nadem Soufir1,2,3.   

Abstract

Genetic predisposition to cutaneous malignant melanoma (CMM) involves highly penetrant predisposing genes and low and intermediate penetrant predisposing alleles. However, the missing heritability in (CMM) is still high. For such and in order to identify new genetic factors for CMM, we conducted an exome sequencing study in high-risk CMM patients. Two rounds of exome sequencing were successively performed in 33 and 27 high-risk patients. We focused on genes carrying rare nonsense, frameshift, and splice variants (allelic frequency <1%) that were present in both series of exomes. An extension study was then conducted in a large cohort (1 079 CMM patients and 1 230 Caucasian ethnically matched healthy controls), and the inactivating variants frequency was compared between groups using two-sided Fisher exact test. Two TP53AIP1 truncating mutations were identified in four patients: a frameshift c.63_64insG, p.Q22Afs*81 in two patients from the same family and in the proband of a second family; and a nonsense mutation c.95 C > A, p.Ser32Stop in a patient with multiple CMMs. In all patients, TP53AIP1 truncating variants were strongly associated with CMM risk (two-sided Fisher exact test = 0.004, OR = 3.3[1.3-8.5]). Additionally, we showed that TP53AIP1 mRNA was strongly down-regulated throughout different phases of melanoma progression. TP53AIP1 gene is a TP53 target which plays a key role by inducting apoptosis in response to UV-induced DNA damage. Constitutional mutations of TP53AIP1 had previously been involved in susceptibility to prostate cancer. Our results show that constitutional truncating TP53AIP1 mutations predispose to CMM in the French population. Replication studies in other populations should be performed.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  TP53AIP1; melanoma; mutation; susceptibility; truncating

Mesh:

Substances:

Year:  2018        PMID: 29359367     DOI: 10.1002/gcc.22528

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

Review 1.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

2.  Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma.

Authors:  Mohamed H Abdel-Rahman; Klarke M Sample; Robert Pilarski; Tomas Walsh; Timothy Grosel; Daniel Kinnamon; Getachew Boru; James B Massengill; Lynn Schoenfield; Ben Kelly; David Gordon; Peter Johansson; Meghan J DeBenedictis; Arun Singh; Silvia Casadei; Frederick H Davidorf; Peter White; Andrew W Stacey; James Scarth; Ellie Fewings; Marc Tischkowitz; Mary-Claire King; Nicholas K Hayward; Colleen M Cebulla
Journal:  Ophthalmology       Date:  2019-11-18       Impact factor: 12.079

3.  Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair.

Authors:  Sophia R Chaudhry; Jaime Lopes; Nancy K Levin; Hasini Kalpage; Michael A Tainsky
Journal:  Cell Death Discov       Date:  2021-03-29

4.  LncRNA TP53TG1 plays an anti-oncogenic role in cervical cancer by synthetically regulating transcriptome profile in HeLa cells.

Authors:  Yi Cheng; Nan Huang; Qingqing Yin; Chao Cheng; Dong Chen; Chen Gong; Huihua Xiong; Jing Zhao; Jianhua Wang; Xiaoyu Li; Jing Zhang; Shuangshuang Mao; Kai Qin
Journal:  Front Genet       Date:  2022-10-04       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.